Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -53.05% | 50.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -53.05% | 50.10% | |||
| Cost of Revenue | -20.26% | 28.76% | |||
| Gross Profit | -80.19% | 73.95% | |||
| SG&A Expenses | -9.42% | -4.29% | |||
| Depreciation & Amortization | -38.37% | 4.24% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.06% | 15.40% | |||
| Operating Income | -139.01% | 526.42% | |||
| Income Before Tax | 78.11% | -1,341.04% | |||
| Income Tax Expenses | -126.62% | 110.61% | |||
| Earnings from Continuing Operations | 81.85% | -2,750.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 81.85% | -2,750.00% | |||
| EBIT | -139.01% | 526.42% | |||
| EBITDA | -110.34% | 168.36% | |||
| EPS Basic | 81.75% | -2,765.80% | |||
| Normalized Basic EPS | -136.20% | 320.11% | |||
| EPS Diluted | 81.67% | -4,800.13% | |||
| Normalized Diluted EPS | -136.20% | 357.54% | |||
| Average Basic Shares Outstanding | -0.58% | -0.58% | |||
| Average Diluted Shares Outstanding | -0.58% | -8.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||